Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 4/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 11/20 | 0.36 |
| ▸ | ADM2 | Q7Z4H4 | 5/20 | 0.36 |
| ▸ | CALCB | P10092 | 4/20 | 0.36 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387275 | 0.83 | CALCA (0.37) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL2774653 | 0.81 | ADM2 (0.40) | CALCRLADM2CALCBRAMP1 | |
| SCHEMBL2895570 | 0.79 | CALCA (0.38) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL1819423 | 0.75 | CALCA (0.52) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL10246001 | 0.74 | CALCRL (0.51) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL16235885 | 0.73 | CALCA (0.46) | CALCACALCRLADM2CALCB | |
| SCHEMBL260524 | 0.73 | CALCA (0.50) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL550614 | 0.73 | CALCA (0.50) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL549390 | 0.73 | CALCA (0.50) | CALCACALCRLADM2CALCBRAMP1 | |
| SCHEMBL29368505 | 0.73 | CALCA (0.50) | CALCACALCRLADM2CALCBRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | CALCA 9/4885CALCRL 4/4885ADM2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.